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doi:10.1016/j.jhep.2006.04.003Antioxidants plus corticoids in the treatment of severe acute
alcoholic hepatitis: The question is still open: ReplyTo the Editor:
We would like to thank Nguyen-Khac et al. for their
interest in our article [1] and respond to their points. We
would agree that there is in vitro evidence that would
suggest that antioxidants (AO) should be of beneﬁt
in vivo. The result of the trial was disappointing. Though
the numbers were small, we feel that there is little to
suggest that patients beneﬁt from AO at this stage of
the disease.
The referenced article by Phillips et al. shows the
beneﬁt of steroids over antioxidants in those patients
that were eligible for steroids [2]. It does not address
the role of antioxidants in patients who cannot receive
steroids and it does not enlighten us as to whether
antioxidants have a role in addition to steroids.
As suggested we were testing two hypotheses con-
comitantly in our study, but not the ones suggested in
the letter; AO vs placebo in those ineligible for steroids
and AO + steroids vs. steroids in those eligible. At no
point were we testing the hypothesis of AO vs. steroids.
This would have included two diﬀerent groups of pa-
tients with diﬀerent mortalities; those that were ineligi-
ble for steroids but were randomized to AO and those
that were eligible for steroids but were randomized to
placebo. We feel that our trial reﬂected the clinical situ-
ation where steroids are given if possible.
Bleeding or sepsis precluded this in 44% of our
patients. This is not a surprising ﬁgure in our unit.
Our trial was designed to pick up a 40% mortality
reduction. While a smaller reduction in mortality would
require larger numbers to detect, the Kaplan–Meier
survival curves are almost superimposed. The authorssuggest a further trial focussing only on patients eligible
for steroids and randomized to receive antioxidants or
placebo. We found the 6-month mortality to be 5/18
(28%) in the steroid only group and 10/20 (50%) in the
steroid and antioxidant group. Further, larger trials
would of course help to clarify this lack of beneﬁt, or per-
haps show some advantage to AO treatment. We feel,
however, that given the paucity of new studies in acute
severe alcoholic hepatitis, and considering the mortality
in a young population, that further eﬀorts should focus
on treatments more likely to have clinical beneﬁt.
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